Facing a 26.5% rebate on 2023 sales of branded prescription drugs in the U.K., the Association of the British Pharmaceutical Industry (ABPI) is seeking talks with the government early in the new year to develop a new biopharma settlement for the future that will reflect the potential of the life sciences sector to drive improvements in the health and economy of the U.K.
The actuary office at CMS reported that U.S. spending on health care grew by a modest rate of 2.7% in 2021, an outcome that would ordinarily prompt cheers by policy wonks who worry about the effect of ever-growing national health expenditures (NHEs) on the larger economy. The problem is that NHE had ballooned by more than 10% in 2020, a rate of growth that was driven in large part by the COVID-19 pandemic, but which statistically overshadowed the growth rate in 2021.
Abbvie Inc. and Hotspot Therapeutics Inc. have entered into an exclusive worldwide collaboration and option to license agreement for Hotspot's discovery-stage interferon regulatory factor 5 (IRF5) program for the treatment of autoimmune diseases.
Shares in Inventiva SA (Paris:IVAA) fell about 18% after development partner Abbvie Inc. quit development of the inflammatory disease drug cedirogant following an unfavorable readout from a phase II toxicology study. The companies had worked on the asset together for about a decade. Inventiva emerged from Abbott in 2012, before the healthcare giant split in 2013 to form pharma specialist Abbvie and Abbott Laboratories, focused on medical devices.
A second death in the study of davoceticept (ALPN-202) has prompted Alpine Immune Sciences Inc. to stop enrolling participants in two phase I studies of the CD28 co-stimulator and dual checkpoint inhibitor, throwing the program’s future into doubt.
U.K.-based seed investor Lifearc Ventures is celebrating a second major deal from its portfolio of companies after Abbvie Inc. bought the tiny former “garage startup" DJS Antibodies Ltd. for $255 million up front plus undisclosed milestone payments. DJS’ lead program is DJS-002, a potential first-in-class lysophosphatidic acid receptor 1 antagonist in preclinical studies for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases.
Many industry watchers are looking to 2023’s Humira biosimilar launch in the U.S. as a portent of the future of biosimilars. While it should help raise awareness of biosimilars in general and produce savings in the immunology sector, its distinctness could make it an outlier in the world of current and future biosimilar competition.
Even though the EU had approved more than a dozen biosimilars by 2012, the follow-on biologics were still in their embryonic stage around the world when BioWorld published The Biosimilars Game: A Scorecard for Opportunities, Threats and Critical Strategies in early 2013. Now, nearly a decade later, the global biosimilar landscape has matured with many more biosimilars approved across the globe, but the uptake, and thus the savings, is not what some policy makers and people in industry had hoped for or expected.
Long considered a make-or-break market for novel drugs and biologics and a success story for generics, the U.S. has been more challenging for biosimilars than many experts initially expected. U.S. biosimilar “uptake has been good, but not great,” Steven Lucio, senior principal for pharmacy solutions at Vizient Inc., told BioWorld. That could change next year when at least seven biosimilars referencing Abbvie Inc.’s immunosuppressive drug, Humira (adalimumab), are expected to launch in the U.S.
Researchers at the Walter and Eliza Hall Institute of Medical Research (WEHI) in Melbourne, Australia, have developed a new genome editing technique than can activate any gene, including those that have been silenced, allowing new drug targets and causes of drug resistance to be explored.
